Theriva Biologics, Inc. announced on November 20, 2026, that its Board of Directors has approved a 1-for-30 reverse stock split of its common stock. The split is effective as of 11:59 p.m. Eastern Time on December 1, 2026, with trading on a split-adjusted basis expected to begin when the market opens on December 2, 2026.

The company stated that the reverse stock split is intended to ensure compliance with the per share price requirements of the NYSE American. Under the terms of the split, each thirty (30) shares of common stock will automatically combine into one (1) new share. As a result, the number of outstanding common shares will be reduced from approximately 45,892,668 to 1,529,756 shares. The number of authorized shares will be proportionally reduced from 350,000,000 to 11,666,666 shares.

Stockholders who hold their shares in brokerage accounts or "street name" are not required to take action. However, the company’s transfer agent, Equiniti Trust Company, will send instructions to stockholders of record who hold physical certificates regarding the exchange of their old certificates for new ones. Fractional shares will not be issued; instead, holders who would otherwise receive a fractional share will receive an additional fractional share to round up to the next whole share. The company’s common stock will continue to trade on the NYSE American under the ticker symbol "TOVX" and will be assigned a new CUSIP number, 87164U607.